U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H22N4O5.CH4O3S
Molecular Weight 494.518
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CAMOSTAT MESYLATE

SMILES

CS(O)(=O)=O.CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1

InChI

InChIKey=FSEKIHNIDBATFG-UHFFFAOYSA-N
InChI=1S/C20H22N4O5.CH4O3S/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22;1-5(2,3)4/h3-10H,11-12H2,1-2H3,(H4,21,22,23);1H3,(H,2,3,4)

HIDE SMILES / InChI
Molecular Formula C20H22N4O5
Molecular Weight 398.4125
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19190233 | https://www.ncbi.nlm.nih.gov/pubmed/3040018

Camostat mesilate (FOY-305) is a synthetic f low-molecular weight protease inhibitor. It is able to inhibit trypsin, prostasin, matriptase and plasma kallikrein. In addition camostat attenuates airway epithelial sodium channel function and enhances mucociliary clearance. Camostat mesilate tablets (FOIPAN®) are approved in Japan and used for the treatment of remission of acute symptoms of chronic pancreatitis and postoperative reflux esophagitis.

CNS Activity

CNS Active
3913
Curator's Comment: Camostat mesilate (FOY-305) is CNS active in animals. No human data available.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Trypsin
7
Target ID: CHEMBL2095204
Inhibitor
8297
 1.0 nM [Ki]
Inhibitor
8297
 4.0 nM [Ki]
Inhibitor
8297
 0.576 µM [Ki]
Inhibitor
8297
 50.0 nM [IC50]
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Approved
8429
FOIPAN

Approved Use

INDICATIONS 1. Remission of acute symptoms of chronic pancreatitis 2. Postoperative reflux esophagitis

Launch Date

1994
Primary
Approved
8429
FOIPAN

Approved Use

INDICATIONS 1. Remission of acute symptoms of chronic pancreatitis 2. Postoperative reflux esophagitis

Launch Date

1994
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
New orally active serine protease inhibitors.
1995 Jul 7
Differential mechanism and site of action of CCK on the pancreatic secretion and growth in rats.
2003 Oct
Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats.
2005 Jun
Calcineurin-dependent and calcineurin-independent signal transduction pathways activated as part of pancreatic growth.
2006 Apr
[Effects of Chinese herbal medicines on spontaneous chronic pancreatitis in rats and the pathological relationships between formulas and syndromes].
2006 Jul
Activation of the mTOR signalling pathway is required for pancreatic growth in protease-inhibitor-fed mice.
2006 Jun 15
Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats.
2006 Mar
Strategies of development of antiviral agents directed against influenza virus replication.
2007
CCK-induced pancreatic growth is not limited by mitogenic capacity in mice.
2008 May
Activation of submucosal but not myenteric plexus of the gastrointestinal tract accompanies reduction of food intake by camostat.
2008 Oct 9
Active site conformational changes of prostasin provide a new mechanism of protease regulation by divalent cations.
2009 May
Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease.
2009 May
ONO 3403, a synthetic serine protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} and nitric oxide production and protects mice from lethal endotoxic shock.
2011 Feb
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
2013 Jul
Patents

Patents

JP2002114755A
2
JP2006213728A
2
WO2008142397A1
2

Sample Use Guides

In Vivo Use Guide
1. Remission of acute symptoms of chronic pancreatitis. The usual dosage for oral use is 600 mg of camostat mesilate daily in three divided doses. The dosage may be adjusted according to the patient’s symptoms. 2. Postoperative reflux esophagitis. The usual dosage for oral use is 300 mg of camostat mesilate daily in three divided doses after each meal.
Route of Administration: Oral
In Vitro Use Guide
Camostat mesilate (500 uM) inhibited generation of TGF-beta by suppressing plasmin activity and reduced the activity of TGF-beta, which blocked in vitro activation of the rat hepatic stellate cells.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:42:12 GMT 2023
Edited
by admin
on Fri Dec 15 15:42:12 GMT 2023
Record UNII
451M50A1EQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAMOSTAT MESYLATE
Common Name English
CAMOSTAT METHANESULFONATE [MI]
Common Name English
CAMOSTAT MESILATE [MART.]
Common Name English
CAMOSTAT MESILATE
MART.   WHO-DD  
Common Name English
CAMOSTAT MESILATE [JAN]
Common Name English
Camostat mesilate [WHO-DD]
Common Name English
CAMOSTAT METHANESULFONATE
MI  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C783
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
Code System Code Type Description
EVMPD
SUB01007MIG
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY
NCI_THESAURUS
C96364
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY
MERCK INDEX
m3000
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY Merck Index
CHEBI
31347
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID0020238
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY
SMS_ID
100000084866
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY
ChEMBL
CHEMBL590799
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY
PUBCHEM
43071
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY
CAS
59721-29-8
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY
FDA UNII
451M50A1EQ
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY
DRUG BANK
DBSALT002914
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY
MESH
C034532
Created by admin on Fri Dec 15 15:42:12 GMT 2023 , Edited by admin on Fri Dec 15 15:42:12 GMT 2023
PRIMARY
Related Record Type Details
Structure of CAMOSTAT
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of CAMOSTAT
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966